Nirav R. Shah, M.D., M.P.H. Commissioner Sue Kelly Executive Deputy Commissioner

Attention: Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

NEW YORK state department of HEALTH

Effective June 20, 2013, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

• Pulmicort Resputes and Zovirax ointment will be added to the Program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense As Written/Product Selection Code of '1'; and **Pharmacies can submit any valid NCPDP field (408-D8) value.**

Accolate	Epivir	Symbyax
Adderall & Adderall XR	Felbatol	Tegretol suspension
Alphagan P 0.15%	Gabitril 2mg, 4mg	Tegretol XR
Astelin	Gris-PEG	Tobradex
Bactroban cream	Kadian	Tricor
Carbatrol	Lovenox	Trileptal suspension
Catapres - TTS	Maxalt MLT	Vancocin
Combivir	Nasacort AQ	Valtrex
Diastat	Pulmicort Respules	Ziagen tablet
Diovan HCT	Sanctura XR	Zovirax ointment
Duetact	Singulair granules	

List of Brand Name Drugs included in this program* (Updated 5/30/13):

*List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.

HEALTH.NY.GOV facebook.com/NYSDOH twitter.com/HealthNYGov